thought leadership
ISPOR EU 2024: Expert strategies to transform evidence and value-based outcomes
September 30, 2024
The biopharmaceutical, diagnostic, and device industries are experiencing a period of great change. Policies are evolving, payer environments are shifting, the concept of value is expanding, and great science is no guarantee of frictionless, in-market patient access.
Our expert team will be at ISPOR EU 2024 in Barcelona, Booth #1412. Our specialists in global and US policy, access, value, and evidence are eager to discuss ways to advance and accomplish your strategic goals.
Meet the global and US specialists at Booth #1412
Advance your research and outcomes strategies by tapping into our expert network at ISPOR EU 2024.
As challenges and the definitions of value continue to evolve, it’s crucial to adapt your access strategies accordingly. From payer to point of care, Avalere Health is ready to guide you through these complexities with our first-class capabilities in HEOR, market access, value engagement, and policy.
Tim Wright
President, Global Policy, Access, Value, and Evidence
Gain insights from our 34 research posters accepted for ISPOR.
We are proud to have 34 research posters accepted for ISPOR EU 2024. View our research at Booth #1412 or contact us for a deeper discussion, tailored to your specific needs. Our research posters at ISPOR EU 2024 span a broad range of insights, including:
Our Avalere Health expertise in health outcomes and novel approaches to leveraging data into insights is on full display at this year’s ISPOR EU. With a record number of acceptances, our collective team has demonstrated the value of our work across a broad and complex set of research questions.
Laura Housman
Senior Vice President, US Evidence & Strategy
Join us for our panel discussion: Refining value assessment by considering indirect costs
Date and time: Tuesday, November 19, 11:45 AM
Panel: 219
Theme: Discover the benefits of broadening the scope of value assessment by incorporating evidence on the indirect burden of disease. We’ll explore its application in US value assessment and ex-US Health Technology Assessment (HTA) submissions.
Key discussion points
- Rare diseases often require a significant amount of medical care, which leads to a higher burden of direct medical costs.
- Indirect costs—such as productivity loss, absenteeism, lifestyle disruptions, and family and societal impacts—contribute to the overall burden of patients with rare disease and their caregivers.
- These broad indirect impacts are often overlooked and under-measured, leading to underestimation of the total disease burden in evidence used for value assessments and HTA submissions.
What you’ll learn
- Recent research measuring the indirect burden of disease
- How real-world evidence on indirect costs can be applied to value assessment and HTA submissions
- The potential impact of incorporating these insights on healthcare decision making
Value assessment is most accurate when we consider costs and benefits in a holistic way. Explore real-world examples of measuring indirect burden in our discussion at ISPOR EU 2024.
Jan McKendrick
Executive Director, Global HEOR
Schedule your meeting at ISPOR EU 2024
Take advantage of our deep knowledge across global and US markets, providing a unique insight into investment decisions, clinical development programs, and product lifecycle planning.
